相似文献
1
Treatment of succinate dehydrogenase B-associated renal cancer.
BMJ Case Rep. 2017 Aug 7;2017:bcr-2017-219626. doi: 10.1136/bcr-2017-219626.
2
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
BJU Int. 2016 Aug;118(2):264-71. doi: 10.1111/bju.13374. Epub 2015 Dec 13.
3
Pazopanib.
Nat Rev Drug Discov. 2010 Jan;9(1):17-8. doi: 10.1038/nrd3073.
4
Pazopanib: therapeutic developments.
Expert Opin Pharmacother. 2009 Dec;10(18):3091-102. doi: 10.1517/14656560903436493.
5
6
Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Tumori. 2014 Nov-Dec;100(6):e301-4. doi: 10.1700/1778.19306.
7
Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
J Urol. 2015 Apr;193(4):1114-21. doi: 10.1016/j.juro.2014.09.110. Epub 2014 Oct 5.
8
[First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Magy Onkol. 2013 Sep;57(3):173-6. Epub 2013 Aug 9.
9
Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.
Clin Genitourin Cancer. 2014 Aug;12(4):e143-6. doi: 10.1016/j.clgc.2014.02.002. Epub 2014 Feb 21.
10
Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape.
Nat Rev Clin Oncol. 2010 Jul;7(7):362-3. doi: 10.1038/nrclinonc.2010.83.
本文引用的文献
1
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.
Eur Urol. 2016 Jul;70(1):106-119. doi: 10.1016/j.eururo.2016.02.028. Epub 2016 Mar 17.
2
Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients.
Am J Surg Pathol. 2014 Dec;38(12):1588-602. doi: 10.1097/PAS.0000000000000292.
3
Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma.
J Clin Oncol. 2014 Feb 20;32(6):e10-3. doi: 10.1200/JCO.2012.47.2647. Epub 2014 Jan 6.
4
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.
J Urol. 2012 Dec;188(6):2063-71. doi: 10.1016/j.juro.2012.08.030. Epub 2012 Oct 18.
5
Renal tumors associated with germline SDHB mutation show distinctive morphology.
Am J Surg Pathol. 2011 Oct;35(10):1578-85. doi: 10.1097/PAS.0b013e318227e7f4.
6
Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4.
N Engl J Med. 2011 Mar 3;364(9):885-6. doi: 10.1056/NEJMc1012357.
7
Renal carcinoma with giant mitochondria associated with germ-line mutation and somatic loss of the succinate dehydrogenase B gene.
Histopathology. 2010 Feb;56(3):405-8. doi: 10.1111/j.1365-2559.2010.03482.x.
8
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
Zotero 插件